Companies · Pharmaceuticals

Sanovia Corp

PHILADELPHIA · Pharmaceuticals

Diligence memoA one-page analyst read on Sanovia Corp — recommendation, valuation, rhythm, risks.
$9.3M
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 49%
Sector rank · raised
Series A
Latest stage · inferred · Wed May 12 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Sanovia Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.19× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.
Dormant
  • Last raise 16.1 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Sanovia Corp is one of 1610 Pharmaceuticals companies tracked from PHILADELPHIA. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2009-04-22 Raised $8.2M (real) Modeled valuation $254M (est)$8.2M$254MSeries A2009Series A · 2010-05-12 Raised $1.1M (real) Modeled valuation $34M (est)$1.1M$34MSeries A2010+$1.1MCumulative $9.3M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.2M · 2009
Series A extension$1.1M · 2010

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$34.1M
Base estimate est.
$1.3M
Conservative case
$185.2M
Upside case
$5.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $253.5M · 2009-04-222009Series A · modeled $34.1M · 2010-05-122010
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
16.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$8.8M/yr
Capital velocity
17.2 yr
On record since
2009
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$9.3M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.1M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$34.1M
Sector median$76.1M

Raised more than 52% of sector peers (real $). Modeled value above 35% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #52 of 57.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Satori Pharmaceuticals Inc · Series A Raised $22.3M · modeled $464.6M (est)Labrys Biologics, Inc. · Series A Raised $14.6M · modeled $451.8M (est)Telsar Pharma, Inc. · Series A Raised $14.0M · modeled $433.7M (est)Acetylon Pharmaceuticals, Inc. · Series A Raised $33.6M · modeled $433.2M (est)Seldar Pharma, Inc. · Series A Raised $18.2M · modeled $402.6M (est)Link Resources Inc. · Series A Raised $12.0M · modeled $371.7M (est)Scynexis Inc · Series A Raised $22.7M · modeled $354.6M (est)Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) · Series A Raised $30.5M · modeled $334.7M (est)BioNumerik Pharmaceuticals, Inc. · Series A Raised $11.3M · modeled $315.6M (est)Quark Pharmaceuticals Inc · Series A Raised $10.0M · modeled $309.7M (est)Bonovo Orthopedics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Tioga Pharmaceuticals Inc · Series A Raised $24.3M · modeled $309.7M (est)Sanovia Corp (this company) Raised $9.3M · modeled $34.1M (est)Sanovia Corp
CompanyStageRaised · realValue · estvs peer med.
Satori Pharmaceuticals IncSeries A$22.3M$464.6M2.58×
Labrys Biologics, Inc.Series A$14.6M$451.8M2.51×
Telsar Pharma, Inc.Series A$14.0M$433.7M2.41×
Acetylon Pharmaceuticals, Inc.Series A$33.6M$433.2M2.40×
Seldar Pharma, Inc.Series A$18.2M$402.6M2.23×
Link Resources Inc.Series A$12.0M$371.7M2.06×
Scynexis IncSeries A$22.7M$354.6M1.97×
Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)Series A$30.5M$334.7M1.86×
BioNumerik Pharmaceuticals, Inc.Series A$11.3M$315.6M1.75×
Quark Pharmaceuticals IncSeries A$10.0M$309.7M1.72×
Bonovo Orthopedics, Inc.Series A$10.0M$309.7M1.72×
Tioga Pharmaceuticals IncSeries A$24.3M$309.7M1.72×
Sanovia Corp this companySeries A$9.3M$34.1M0.19×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.2M2009-04-22$37.2M$253.5M90%
Series A$1.1M2010-05-12$5.0M$34.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.2M2009-04-22
    • First recorded raise — entered as Series A.
  2. Series A$1.1M2010-05-12
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round 7.4× smaller than the prior — bridge or down round.
Intelligence
2011 ~Q2
Modeled next raise · ~13mo cadence
$1.1M
Modeled next size est.range $1.1M$1.8M
0.1×
Last step-up
$8.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Chadwick4 other2009-04
Peter J. Grua3 other2009-04
Rebecca Shanahan1 other2009-04
David J. Jones, Jr.2010-05
Donald J. Taylor2010-05
Paul Anthony Polansky2009-04
Robert Tremain2009-04
Shabbir Ahmed2009-04
William J. Brown2010-05
Registry & provenance

Sanovia Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1332413
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Intezyne Technologies, Inc.PharmaceuticalsSeries A$9.3M$14.9Msame sector · same stage
THC PharmaceuticalPharmaceuticalsSeries A$9.0M$18.9Msame sector · same stage
Modulo Bio, Inc.PharmaceuticalsSeries A$9.8M$25.7Msame sector · same stage
Avicanna Inc.PharmaceuticalsSeries A$9.9M$24.3Msame sector · same stage
Slate Medicines, Inc.PharmaceuticalsSeries A$10.0M$24.8Msame sector · same stage
60 Degrees Pharmaceuticals LLCPharmaceuticalsSeries A$10.0M$21.0Msame sector · same stage
LARASAN PHARMACEUTICAL CorpPharmaceuticalsSeries A$10.0M$21.0Msame sector · same stage
Natural Solutions Corp.PharmaceuticalsSeries A$10.0M$21.0Msame sector · same stage
Frequently asked
How much funding has Sanovia Corp raised?
Sanovia Corp has raised approximately $9.3M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Sanovia Corp's estimated valuation?
Provath's modeled valuation for Sanovia Corp is approximately $34.1M (modeled range $1.3M–$185.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Sanovia Corp at?
Sanovia Corp's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed May 12.
What does Sanovia Corp do and where is it based?
Sanovia Corp operates in the Pharmaceuticals sector, based in PHILADELPHIA.
Explore related

See where Sanovia Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Sanovia Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.